CD200 is a new prognostic factor in multiple myeloma.

Jérôme Moreaux, Dirk Hose, Thierry Rème, Eric Jourdan, Michael Hundemer, Eric Legouffe, Philippe Moine, Philippe Bourin, Marion Moos, Jill Corre, et al.

► To cite this version:

Jérôme Moreaux, Dirk Hose, Thierry Rème, Eric Jourdan, Michael Hundemer, et al.. CD200 is a new prognostic factor in multiple myeloma.. *Blood*, 2006, 108 (13), pp.4194-7. 10.1182/blood-2006-06-029355 . inserm-00130595

HAL Id: inserm-00130595

<https://www.hal.inserm.fr/inserm-00130595>

Submitted on 6 Mar 2007

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CD200 is a new prognostic factor in Multiple Myeloma

Moreaux J[‡], Hose D[°], RemeT^{*‡}, Jourdan E[◇], Hundemer M[°], Legouffe E[§], Moine P^{*}, Bourin P[^], Moos M[°], Corre J[^], Möhler T[°], De Vos J^{*‡}, Rossi JF^{§†}, Goldschmidt H^{°&}, Klein B^{*‡}

* CHU Montpellier, Institute of Research in Biotherapy, Montpellier, FRANCE;

‡ INSERM, U475, Montpellier, F-34197 France;

° Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany

◇ CHU Nîmes, Internal Medicine Department B, Nîmes, France;

§ CHU Montpellier, Department of Hematology and Clinical Oncology, Montpellier, FRANCE;

^ Laboratoire de Thérapie Cellulaire-Etablissement Français du sang, Pyrénées-Méditerranée, Toulouse, France;

† Université MONTPELLIER1, UFR Médecine, Montpellier, France;

& Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany

Corresponding author: Bernard KLEIN
INSERM U475
99, rue Puech Villa
34197 MONTPELLIER Cedex 5
FRANCE
Phone: +33 4 67 63 61 25
Fax: + 33 4 67 04 18 63
e-mail: klein@montp.inserm.fr

Acknowledgements: This work was supported by grants from the Ligue Nationale Contre Le Cancer (équipe labellisée), Paris, France. It is part of a national program called « Carte d'Identité des Tumeurs » program (CIT) or the Tumor Identity Card developed and funded by the Ligue Nationale Contre le Cancer (<http://www.ligue-cancer.net>).

Abstract word count: 150 words

Text word count: 1352 words

Author contributions:

MJ performed the experiments and participated in the writing of the paper.

HD, HM, and GH collected bone marrow samples and clinical data and participated in the writing of the paper.

RT and DVJ performed the bio-informatic studies and participated in the writing of the paper.

JE, LE, RJF and MT collected bone marrow samples and clinical data.

MP provided with technical assistance.

MM participated in the writing of the paper.

BP and CJ collected bone marrow samples.

KB participated in the design of the research and the writing of the paper.

Abstract

Using Affymetrix microarrays, we identified the expression of the *CD200* gene in multiple myeloma cells (MMC) of 112 patients with newly-diagnosed multiple myeloma (MM). The *CD200* gene was either absent or present (Affymetrix call) in 22% and 78% of MMC, respectively. The *CD200* gene is not expressed in cells of the patients' bone marrow (BM). CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. Patients with CD200^{absent} MMC have an increased event free survival (24 months) compared to patients with CD200^{present} MMC (14 months), after high-dose therapy and stem cell transplantation. In a Cox-proportional-hazard model, the absence or presence of *CD200* expression in MMC is predictive for EFS for patients independently of ISS stage or B2M serum levels. Thus, *CD200* is an independent prognosis factor for patients with MM that could represent a new therapeutic target in MM.

Introduction

Multiple myeloma (MM) is a plasma cell neoplasm characterized by the accumulation of malignant plasma cells within the bone marrow (BM). Several autocrine or paracrine factors can promote multiple myeloma cell (MMC) survival and proliferation^{1,2}. We anticipate that in the future, the inhibition of MMC growth factors may have clinical applications in combination with other drugs³⁻⁶.

In order to identify new molecules involved in the communication between MMC and the BM environment, we compared gene expression profiles (GEP) of MMC with those of normal plasma cells, normal plasmablasts and normal peripheral blood B cells. We identified that *CD200* was expressed in malignant plasma cells in 78% of newly-diagnosed patients with MM. CD200, formerly known as OX-2, is a highly conserved type I transmembrane glycoprotein that is expressed by thymocytes, activated T cells, B cells, dendritic cells, endothelial cells and neurons⁷. The expression of the receptor for CD200 (CD200R1) is described as restricted to myeloid-derived antigen presenting cells and certain populations of T cells⁸. Three other genes, closely related to CD200R1 and termed CD200R2-4 have been identified, but the function of these encoded proteins, in particular their ability to bind CD200, is not fully elucidated⁹. Several studies have shown that CD200 imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. Increased survival of renal allografts following portal vein immunization with alloantigen correlates with an increase in *CD200* expression in both hepatic and splenic dendritic cells (DCs) in a murine model¹⁰. Tolerance in this setting is reversed with a monoclonal antibody to CD200¹¹. CD200-deficient mice have a compromised capacity to down-regulate the activation of antigen presenting cells. This results in chronic central nervous system inflammation, which causes an

exaggerated inflammatory response to trauma and an increased susceptibility to develop both experimental autoimmune encephalitis and collagen-induced arthritis¹². More recently, Gorczynski *et al.* demonstrated that anti-CD200R(2-4) monoclonal antibodies (MoAb) promote the development of DCs and have the capacity to induce regulatory T cells (Treg) and directly augment the production of Treg in the thymus¹³. In this study, we demonstrate that MMC of 78% of the patients with newly-diagnosed MM express *CD200*. For patients included in protocols with high dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT), the presence or absence of CD200 expression is a prognostic factor independent of ISS stage or B2M.

Materials and methods

Cell samples

XG human myeloma cell lines (HMCL) were obtained as described¹⁴⁻¹⁶. SKMM, OPM2, LP1 and RPMI8226 HMCL were purchased from ATTC (LGC Promochem, France). MMC were purified from 112 patients with newly-diagnosed MM after written informed consent was given. These 112 patients were treated with HDC and ASCT. Seven of these 112 patients received allogenic bone marrow transplantation after HDC and ASCT and their event free survival was censored at the time of the allograft. In the series, according to the Durie-Salmon classification, 9 patients were of stage IA, 14 of stage IIA, 83 of stage IIIA, and 6 of stage IIIB. According to the International Staging System (ISS)¹⁷, 44 patients were of stage I, 53 of stage II, 15 of stage III. 17 patients had IgA κ MM, 6 IgA λ MM, 38 IgG κ MM, 26 IgG λ MM, 14 Bence-Jones κ MM, 7 Bence-Jones λ MM, and 4 non-secreting MM. The obtainment and purification of MMC, normal bone marrow (BM) plasma cells (BMPC), memory B cells, polyclonal plasmablasts, osteoclasts, BM stromal cell lines, BM CD3 T cells,

BM monocytes and BM polymorphonuclear neutrophils were performed as previously described¹⁸.

Preparation of complementary RNA (cRNA) and microarray hybridization

RNA was extracted using the RNeasy Kit (Qiagen, Hilden, Germany). Biotinylated cRNA was amplified with a double *in vitro* transcription reaction and hybridized to the Affymetrix HG U133 set of Gene Chips, according to the manufacturer's instructions (Affymetrix, Santa Clara, CA).

CD200 expression by MMC

CD200 expression by primary MMC was determined using a double labeling of primary MMC with a FITC-conjugated anti-CD138 MoAb and a PE-conjugated anti-CD200 MoAb (clone MRCOX-104, Becton Dickinson, San Jose, CA), or with FITC- or PE- conjugated isotype matched control antibodies. The fluorescence intensity was determined with a FACScan device (Becton Dickinson), setting up the mean fluorescence intensity obtained with the control antibodies between 4 and 6.

Statistical analysis

Gene expression data were normalized with the MAS5 algorithm and analyzed with our bioinformatics platforms (RAGE, <http://rage.montp.inserm.fr/> and Amazonia, <http://amazonia.montp.inserm.fr/>). Statistical comparisons were done with R (<http://www.r-project.org/>) or SPSS10 (SPSS Chicago, IL) software.

Results and Discussion

Comparing the GEP of MMC in an initial series of 48 patients with newly-diagnosed MM with the GEP of normal BM plasma cells, normal plasmablasts and normal memory B cells using Affymetrix U133 A+B DNA-microarrays, we found a clear cut expression of *CD200* in MMC. In 9/48 patients, *CD200* had an “absent” Affymetrix call (*CD200*^{absent}) in MMC. In the remaining 39 patients, *CD200* had a “present” call (*CD200*^{present}) in MMC and was overexpressed in MMC compared to normal BMPC (ratio = 6.2 and $P < .01$), plasmablasts (ratio = 26.5 and $P < .01$) or memory B cells (ratio = 10 and $P < .01$) (Figure 1 A). These data were confirmed with another independent series of MMC from 64 newly-diagnosed patients using Affymetrix U133 2.0 plus microarrays (Figure 1 A). Combining the two sets of data, *CD200* had a “present” call in MMC in 87 out of 112 (78%) patients. Microarrays *CD200* expression was validated by real-time RT-PCR for 20 HMCL and 5 patients’ MMC ($r = .81$, $P < .001$) (Supplementary data, Figure S1). Using FACS analysis, the *CD200* protein was detected on MMC in 13/15 (86%) consecutive newly-diagnosed patients, confirming the frequency of *CD200* expression determined by “absent”/“present” calls with Affymetrix microarrays (Table 1). If *CD200* is expressed in MMC, the mean fluorescence intensity ranged from 364 to 8038 (Table 1) (Figure 1B). On the panel of 20 HMCL used, only HMCL with detectable *CD200* mRNA displayed a positive labeling with the anti-*CD200* MoAb. Moreover, we found a very good correlation ($r = .92$; $P < .001$) between Affymetrix *CD200* expression and protein expression (Mean fluorescence intensity) at the surface of our HMCL (Supplementary data, Figure S2). Subsequently, we investigated the *CD200* gene expression in the BM environment from patients with MM. *CD200* was not expressed by CD14 monocytes, CD15 polynuclear cells and CD3 T cells that were purified from the BM of 5 newly-

diagnosed patients. It is also not expressed in 7 osteoclast samples (Figure 1 A). BM stromal cells from 5 patients with MM expressed *CD200*, but at a 3.9 fold lower median signal compared to that in *CD200*^{present} MMC ($P = .04$). *CD34*⁺ hematopoietic stem cells from 5 patients with MM expressed *CD200*, but at a 2.5 fold lower median signal compared to that in *CD200*^{present} MMC ($P = .05$).

A significantly higher number of patients with *CD200*^{present} had a monoclonal protein containing lambda-light chains, whereas an age ≥ 65 years appeared at a significantly higher frequency in patients with *CD200*^{absent} MMC (Supplementary data Table A). In our group of 112 newly-diagnosed patients treated with HDT and ASCT, patients with *CD200*^{absent} MMC had a better event free survival (24 months) compared to patients with *CD200*^{present} MMC (14 months) (Figure 1C). In a Cox-proportional-hazard model monitoring for the absence or presence of *CD200* ($P = 0.04$) and ISS-stage ($P = 0.01$), both parameters are independently predictive for EFS ($P = 0.01$). If *CD200* expression is tested together with classical prognostic factors, *i.e.* serum albumin and serum $\beta 2M$, *CD200* expression ($P = 0.04$) and $\beta 2M$ ($P = 0.015$) remain independent prognostic factors, whereas serum albumin marginally fails to be significant ($P = 0.058$).

This better EFS of patients with MMC lacking *CD200* could be linked to the role of *CD200* in suppression of T-cell-mediated immune responses and in the development of DC with a capacity to induce Treg^{9-11,13}. A recent study has demonstrated that B cell chronic lymphocytic leukemia expresses *CD200* that leads to inhibition of the Th1 response in mixed lymphocyte reactions¹⁹. In conclusion, we have identified that *CD200* expression by MMC is an independent prognostic factor for patients with MM that could represent a new therapeutic target.

Patient	CD200 labeling	
	%	MFI
1	84.8	2273
2	90.4	4347
3	88.8	986
4	97.7	2023
5	80	1219
6	98.1	1155
7	< 5	-
8	99.6	8038
9	< 5	-
10	95.9	804
11	95.6	832
12	30.7	364
13	99.9	1259
14	62	601
15	97.8	442

Table 1: CD200 expression at the surface of myeloma cells.

CD200 expression by primary MMC was determined using a double labeling of primary MMC with a FITC-conjugated anti-CD138 MoAb and a PE-conjugated anti-CD200 MoAb, or with FITC- or PE-conjugated isotype matched control antibodies. The fluorescence intensity was determined with a FACScan device, setting up the mean fluorescence intensity obtained with the control antibodies between 4 and 6.

Figure legends

Figure 1. CD200 expression and association with event free survival in patients with MM.

(A) Affymetrix *CD200* gene expression in normal memory B cells, normal polyclonal plasmablasts, normal BM plasma cells (BMPC), purified myeloma cells from patients with multiple myeloma (MM), human myeloma cell lines, BM stromal cells, BM CD34 cells, purified BM CD15, CD14 and CD3 cells and osteoclasts.

(B) CD200 expression by primary MMC or normal BMPC was determined using a double labeling of primary MMC with a FITC-conjugated anti-CD138 MoAb and a PE-conjugated anti-CD200 MoAb, or with FITC- or PE- conjugated isotype matched control antibodies.

(C) Kaplan-Meier plot of the event free survival in patients with *CD200*^{present} and *CD200*^{absent} MMC.

References

1. Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. *Int J Hematol.* 2003;78:106-113.
2. De Vos J, Hose D, Reme T, et al. Microarray-based understanding of normal and malignant plasma cells. *Immunol Rev.* 2006;210:86-104.
3. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. *Blood.* 1991;78:1198-1204.
4. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. *Blood.* 1995;86:685-691.
5. Rossi JF, Fegueux N, Lu ZY, et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m² of melphalan in multiple myeloma: results of a pilot study including biological aspects. *Bone Marrow Transplant.* 2005;36:771-779.
6. Rossi JF, Moreaux J, Requirand G, Bouseida S, Picard M, Ythier A, Sievers E, Klein B. A phase I/II study of TACI-Ig to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma or active previously-treated waldenström's macroglobulinemia. *Blood.* 2005;106.
7. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. *Trends Immunol.* 2002;23:285-290.

8. Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. *J Immunol.* 2003;171:3034-3046.
9. Gorczynski RM. CD200 and its receptors as targets for immunoregulation. *Curr Opin Investig Drugs.* 2005;6:483-488.
10. Gorczynski RM, Chen Z, Fu XM, Zeng H. Increased expression of the novel molecule OX-2 is involved in prolongation of murine renal allograft survival. *Transplantation.* 1998;65:1106-1114.
11. Gorczynski RM, Cohen Z, Fu XM, Lei J. Anti-rat OX-2 blocks increased small intestinal transplant survival after portal vein immunization. *Transplant Proc.* 1999;31:577-578.
12. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). *Science.* 2000;290:1768-1771.
13. Gorczynski RM, Lee L, Boudakov I. Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. *Transplantation.* 2005;79:1180-1183.
14. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. *Blood.* 1994;83:3654-3663.
15. Rebouissou C, Wijdenes J, Autissier P, et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. *Blood.* 1998;91:4727-4737.
16. Gu ZJ, Vos JD, Rebouissou C, et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. *Leukemia.* 2000;14:188-197.
17. Greipp PR SMJ, Fonseca R, Avet-Loiseau H, Jacobson JL, Rasmussen E, Crowley J, Durie BMG. Development of an international prognostic index (IPI) for myeloma: report of the international myeloma working group. *Hematology Journal.* 2003;4.
18. Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. *Blood.* 2005;106:1021-1030.
19. McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. *Proc Natl Acad Sci U S A.* 2006;103:1041-1046.

Fig 1 B

Fig 1 C